US lawmakers reveal policy to curb collaboration with Chinese biotech
US lawmakers reveal policy to curb collaboration with Chinese biotech
Publish Date: 2026-06-03 09:40:00
Source Domain: www.pharmaceutical-technology.com
Michigan lawmakers are looking to enact a policy that would restrict American dealmaking with Chinese biotech and pharma companies. Credit: OnePixelStudio / Shutterstock.com.
Two bipartisan Michigan lawmakers have joined forces to debut new legislation that, if enacted, could significantly suppress dealmaking between Chinese and American biotech and pharma companies.
Together, Republican John Moolenaar and Democrat Debbie Dingell have proposed the Biotech Investment National Security Act (BINSA). Acting as an amendment to the Comprehensive Outbound Investment National Security (COINS) Act of December 2025, which set out in part to curb China’s burgeoning dominance in the tech field, BINSA would allow US lawmakers to monitor and impose severe restrictions on American investments into foreign technology sectors.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Find out more
According to Moolenaar, legislation like BINSA would “protect research, innovation and the medicines Americans depend on”, as US pharma companies increasingly turn to China for their innovative pipeline assets.
In a statement, Moolenaar specifically called out recent, high-profile deals made by pharmaceutical giants Pfizer and Bristol Myers Squibb (BMS) as “dangerous” and a potential threat to the future of pharmaceutical production in the US – referring to BMS’s recent mega-deal worth up to $15.2bn with…
